Stifel raised the firm’s price target on Medtronic (MDT) to $105 from $90 and keeps a Hold rating on the shares. After hosting an investor group visit and tour of Medtronic’s Boston HUGO soft tissue surgical robotic facility, the firm says Medtronic “appears confidently ready,” from a supply-chain, manufacturing, and physician support and training roll-out perspective, to launch HUGO in the U.S.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic initiates U.S. IDE study of Hugo robotic-assisted surgery system
- Medtronic price target raised to $112 from $101 at Citi
- Medtronic’s Strategic Growth Potential with Spyral RDN Technology Justifies Buy Rating
- Medtronic call volume above normal and directionally bullish
- Medtronic Issues €1.5 Billion in Senior Notes